[
    {
        "model": "portal.PriorAuthRequirement",
        "pk": 1,
        "fields": {
            "url_slug": "bf465e610535eb38",
            "description": "UnitedHealthcare Pharmacy Prior Authorization Requirements for Wegovy in the state of California",
            "insurance_provider": "UnitedHealthcare Pharmacy",
            "insurance_plan_number": "2023 P 1114-12",
            "insurance_coverage_state": "California",
            "medication": "Wegovy",
            "requirements_flow_file_location": "graphs/wegovy-united-healthcare.svg",
            "requirements_flow": "digraph G {rankstep=1;node [shape=box,style = \"filled,rounded\",color = \"steelblue4\"fontcolor = \"mintcream\",fontname = \"Arial\",margin = 0.1fontsize = 40,width = 0.2,height = 0.2,];edge [arrowhead=vee,fontname=\"Arial\",fontsize=40,color=\"steelblue4\"];q1 [label=\"Prescription from Endocrinologist or Weight Management Specialist?\"]q2 [label=\"Patient at least 18 years of age?\"]q3 [label=\"Baseline BMI 30 kg/m2 or greater with at least one weight-related comorbidity?\"]q4 [label=\"Patient has attempted to lose weight through KP-approved weight loss program?\"]q5 [label=\"Patient has documented intolerance or contraindication to all listed medications?\"]q6 [label=\"Wegovy not used with another weight loss drug or GLP-1 receptor agonist?\"]q7 [label=\"Initial prescription is limited to a maximum of 30-day supply with 2 refills?\"]q8 [label=\"For Type 2 DM patients,do they meet both additional criteria?\"]q9 [label=\"Patient continues to meet initial review criteria?\"]q10 [label=\"Documented weight loss of at least 10% from baseline weight in the past 3 months?\"]ineligible [label=\"Ineligible\", color=\"red\"]eligible [label=\"Eligible\", color=\"darkgreen\"]q1 -> q2 [label=\"Yes\"]q1 -> ineligible [label=\"No\"]q2 -> q3 [label=\"Yes\"]q2 -> ineligible [label=\"No\"]q3 -> q4 [label=\"Yes\"]q3 -> ineligible [label=\"No\"]q4 -> q5 [label=\"Yes\"]q4 -> ineligible [label=\"No\"]q5 -> q6 [label=\"Yes\"]q5 -> ineligible [label=\"No\"]q6 -> q7 [label=\"Yes\"]q6 -> ineligible [label=\"No\"]q7 -> q8 [label=\"Yes\"]q7 -> ineligible [label=\"No\"]q8 -> q9 [label=\"Yes\"]q8 -> ineligible [label=\"No\"]q9 -> q10 [label=\"Yes\"]q9 -> ineligible [label=\"No\"]q10 -> eligible [label=\"Yes\"]q10 -> ineligible [label=\"No\"]}",
            "requirements_checklist": {
                "label": "Is this request for initiation or continuation of therapy with Wegovy™ (semaglutide)?",
                "node_type": "fieldset",
                "children": [
                    {
                        "label": "Start of therapy",
                        "outcome": "Authorization for Wegovy™ (semaglutide), is expected to be issued for 4 months",
                        "node_type": "radio",
                        "node_value": false,
                        "children": [
                            {
                                "label": "Treatment is being requested for appetite suppression or weight loss",
                                "node_type": "checkbox",
                                "node_value": false
                            },
                            {
                                "label": "Patient is ≥ 12 years of age",
                                "node_type": "checkbox",
                                "node_value": false
                            },
                            {
                                "label": "Used as an adjunct to lifestyle modification (e.g., dietary or caloric restriction, exercise, behavioral support, community-based program)",
                                "node_type": "checkbox",
                                "node_value": false
                            },
                            {
                                "label": "One of the following",
                                "node_type": "checkbox",
                                "node_value": false,
                                "children": [
                                    {
                                        "label": "Body Mass Index (BMI) ≥ 30 kg/m2 or for pediatric patients a BMI > 95th percentile",
                                        "node_type": "checkbox",
                                        "node_value": false
                                    },
                                    {
                                        "label": "BMI ≥ 27 kg/m2 and patient has a weight-related comorbidity (e.g., dyslipidemia, hypertension, type 2 diabetes, sleep apnea)",
                                        "node_type": "checkbox",
                                        "node_value": false
                                    }
                                ]
                            }
                        ]
                    },
                    {
                        "label": "Continuation of therapy",
                        "outcome": "Authorization for Wegovy™ (semaglutide), is expected to be issued for 12 months",
                        "node_type": "radio",
                        "node_value": false,
                        "children": [
                            {
                                "label": "Weight loss of ≥ 4% of baseline body weight for Wegovy",
                                "node_type": "checkbox",
                                "node_value": false
                            },
                            {
                                "label": "Continuation of lifestyle modification",
                                "node_type": "checkbox",
                                "node_value": false
                            }
                        ]
                    }
                ]
            }
        }
    },
    {
        "model": "portal.PriorAuthRequirement",
        "pk": 2,
        "fields": {
            "url_slug": "ba9bcdb91a7fbe33",
            "description": "UnitedHealthcare Pharmacy Prior Authorization Requirements for Wegovy in the state of New York",
            "insurance_provider": "UnitedHealthcare Pharmacy",
            "insurance_plan_number": "2023 P 1114-12",
            "insurance_coverage_state": "New York",
            "medication": "Wegovy",
            "requirements_flow": "digraph G {rankstep=1;node [shape=box,style = \"filled,rounded\",color = \"steelblue4\"fontcolor = \"mintcream\",fontname = \"Arial\",margin = 0.1fontsize = 40,width = 0.2,height = 0.2,];edge [arrowhead=vee,fontname=\"Arial\",fontsize=40,color=\"steelblue4\"];q1 [label=\"Prescription from Endocrinologist or Weight Management Specialist?\"]q2 [label=\"Patient at least 18 years of age?\"]q3 [label=\"Baseline BMI 30 kg/m2 or greater with at least one weight-related comorbidity?\"]q4 [label=\"Patient has attempted to lose weight through KP-approved weight loss program?\"]q5 [label=\"Patient has documented intolerance or contraindication to all listed medications?\"]q6 [label=\"Wegovy not used with another weight loss drug or GLP-1 receptor agonist?\"]q7 [label=\"Initial prescription is limited to a maximum of 30-day supply with 2 refills?\"]q8 [label=\"For Type 2 DM patients,do they meet both additional criteria?\"]q9 [label=\"Patient continues to meet initial review criteria?\"]q10 [label=\"Documented weight loss of at least 10% from baseline weight in the past 3 months?\"]ineligible [label=\"Ineligible\", color=\"red\"]eligible [label=\"Eligible\", color=\"darkgreen\"]q1 -> q2 [label=\"Yes\"]q1 -> ineligible [label=\"No\"]q2 -> q3 [label=\"Yes\"]q2 -> ineligible [label=\"No\"]q3 -> q4 [label=\"Yes\"]q3 -> ineligible [label=\"No\"]q4 -> q5 [label=\"Yes\"]q4 -> ineligible [label=\"No\"]q5 -> q6 [label=\"Yes\"]q5 -> ineligible [label=\"No\"]q6 -> q7 [label=\"Yes\"]q6 -> ineligible [label=\"No\"]q7 -> q8 [label=\"Yes\"]q7 -> ineligible [label=\"No\"]q8 -> q9 [label=\"Yes\"]q8 -> ineligible [label=\"No\"]q9 -> q10 [label=\"Yes\"]q9 -> ineligible [label=\"No\"]q10 -> eligible [label=\"Yes\"]q10 -> ineligible [label=\"No\"]}",
            "requirements_flow_file_location": "graphs/wegovy-united-healthcare.svg",
            "requirements_checklist": {
                "label": "Is this request for initiation or continuation of therapy with Wegovy™ (semaglutide)?",
                "node_type": "fieldset",
                "children": [
                    {
                        "label": "Start of therapy",
                        "outcome": "Authorization for Wegovy™ (semaglutide), is expected to be issued for 4 months",
                        "node_type": "radio",
                        "node_value": false,
                        "children": [
                            {
                                "label": "Treatment is being requested for appetite suppression or weight loss",
                                "node_type": "checkbox",
                                "node_value": false
                            },
                            {
                                "label": "Patient is ≥ 12 years of age",
                                "node_type": "checkbox",
                                "node_value": false
                            },
                            {
                                "label": "Used as an adjunct to lifestyle modification (e.g., dietary or caloric restriction, exercise, behavioral support, community-based program)",
                                "node_type": "checkbox",
                                "node_value": false
                            },
                            {
                                "label": "One of the following",
                                "node_type": "checkbox",
                                "node_value": false,
                                "children": [
                                    {
                                        "label": "Body Mass Index (BMI) ≥ 30 kg/m2 or for pediatric patients a BMI > 95th percentile",
                                        "node_type": "checkbox",
                                        "node_value": false
                                    },
                                    {
                                        "label": "BMI ≥ 27 kg/m2 and patient has a weight-related comorbidity (e.g., dyslipidemia, hypertension, type 2 diabetes, sleep apnea)",
                                        "node_type": "checkbox",
                                        "node_value": false
                                    }
                                ]
                            }
                        ]
                    },
                    {
                        "label": "Continuation of therapy",
                        "outcome": "Authorization for Wegovy™ (semaglutide), is expected to be issued for 12 months",
                        "node_type": "radio",
                        "node_value": false,
                        "children": [
                            {
                                "label": "Weight loss of ≥ 4% of baseline body weight for Wegovy",
                                "node_type": "checkbox",
                                "node_value": false
                            },
                            {
                                "label": "Continuation of lifestyle modification",
                                "node_type": "checkbox",
                                "node_value": false
                            }
                        ]
                    }
                ]
            }
        }
    },
    {
        "model": "portal.PriorAuthRequirement",
        "pk": 3,
        "fields": {
            "url_slug": "f6a4f837da68fc56",
            "description": "UnitedHealthcare Pharmacy Prior Authorization Requirements for Wegovy in the state of New Mexico",
            "insurance_provider": "UnitedHealthcare Pharmacy",
            "insurance_plan_number": "2023 P 1114-12",
            "insurance_coverage_state": "New Mexico",
            "medication": "Wegovy",
            "requirements_flow": "digraph G {rankstep=1;node [shape=box,style = \"filled,rounded\",color = \"steelblue4\"fontcolor = \"mintcream\",fontname = \"Arial\",margin = 0.1fontsize = 40,width = 0.2,height = 0.2,];edge [arrowhead=vee,fontname=\"Arial\",fontsize=40,color=\"steelblue4\"];q1 [label=\"Prescription from Endocrinologist or Weight Management Specialist?\"]q2 [label=\"Patient at least 18 years of age?\"]q3 [label=\"Baseline BMI 30 kg/m2 or greater with at least one weight-related comorbidity?\"]q4 [label=\"Patient has attempted to lose weight through KP-approved weight loss program?\"]q5 [label=\"Patient has documented intolerance or contraindication to all listed medications?\"]q6 [label=\"Wegovy not used with another weight loss drug or GLP-1 receptor agonist?\"]q7 [label=\"Initial prescription is limited to a maximum of 30-day supply with 2 refills?\"]q8 [label=\"For Type 2 DM patients,do they meet both additional criteria?\"]q9 [label=\"Patient continues to meet initial review criteria?\"]q10 [label=\"Documented weight loss of at least 10% from baseline weight in the past 3 months?\"]ineligible [label=\"Ineligible\", color=\"red\"]eligible [label=\"Eligible\", color=\"darkgreen\"]q1 -> q2 [label=\"Yes\"]q1 -> ineligible [label=\"No\"]q2 -> q3 [label=\"Yes\"]q2 -> ineligible [label=\"No\"]q3 -> q4 [label=\"Yes\"]q3 -> ineligible [label=\"No\"]q4 -> q5 [label=\"Yes\"]q4 -> ineligible [label=\"No\"]q5 -> q6 [label=\"Yes\"]q5 -> ineligible [label=\"No\"]q6 -> q7 [label=\"Yes\"]q6 -> ineligible [label=\"No\"]q7 -> q8 [label=\"Yes\"]q7 -> ineligible [label=\"No\"]q8 -> q9 [label=\"Yes\"]q8 -> ineligible [label=\"No\"]q9 -> q10 [label=\"Yes\"]q9 -> ineligible [label=\"No\"]q10 -> eligible [label=\"Yes\"]q10 -> ineligible [label=\"No\"]}",
            "requirements_flow_file_location": "graphs/wegovy-united-healthcare.svg",
            "requirements_checklist": {
                "label": "Is this request for initiation or continuation of therapy with Wegovy™ (semaglutide)?",
                "node_type": "fieldset",
                "children": [
                    {
                        "label": "Start of therapy",
                        "outcome": "Authorization for Wegovy™ (semaglutide), is expected to be issued for 4 months",
                        "node_type": "radio",
                        "node_value": false,
                        "children": [
                            {
                                "label": "Treatment is being requested for appetite suppression or weight loss",
                                "node_type": "checkbox",
                                "node_value": false
                            },
                            {
                                "label": "Patient is ≥ 12 years of age",
                                "node_type": "checkbox",
                                "node_value": false
                            },
                            {
                                "label": "Used as an adjunct to lifestyle modification (e.g., dietary or caloric restriction, exercise, behavioral support, community-based program)",
                                "node_type": "checkbox",
                                "node_value": false
                            },
                            {
                                "label": "One of the following",
                                "node_type": "checkbox",
                                "node_value": false,
                                "children": [
                                    {
                                        "label": "Body Mass Index (BMI) ≥ 30 kg/m2 or for pediatric patients a BMI > 95th percentile",
                                        "node_type": "checkbox",
                                        "node_value": false
                                    },
                                    {
                                        "label": "BMI ≥ 27 kg/m2 and patient has a weight-related comorbidity (e.g., dyslipidemia, hypertension, type 2 diabetes, sleep apnea)",
                                        "node_type": "checkbox",
                                        "node_value": false
                                    }
                                ]
                            }
                        ]
                    },
                    {
                        "label": "Continuation of therapy",
                        "outcome": "Authorization for Wegovy™ (semaglutide), is expected to be issued for 12 months",
                        "node_type": "radio",
                        "node_value": false,
                        "children": [
                            {
                                "label": "Weight loss of ≥ 4% of baseline body weight for Wegovy",
                                "node_type": "checkbox",
                                "node_value": false
                            },
                            {
                                "label": "Continuation of lifestyle modification",
                                "node_type": "checkbox",
                                "node_value": false
                            }
                        ]
                    }
                ]
            }
        }
    },
    {
        "model": "portal.PriorAuthRequirement",
        "pk": 4,
        "fields": {
            "url_slug": "8f13ea2d174df741",
            "description": "UnitedHealthcare Pharmacy Prior Authorization Requirements for Wegovy in the state of Maryland",
            "insurance_provider": "UnitedHealthcare Pharmacy",
            "insurance_plan_number": "2023 P 1114-12",
            "insurance_coverage_state": "Maryland",
            "medication": "Wegovy",
            "requirements_flow": "digraph G {rankstep=1;node [shape=box,style = \"filled,rounded\",color = \"steelblue4\"fontcolor = \"mintcream\",fontname = \"Arial\",margin = 0.1fontsize = 40,width = 0.2,height = 0.2,];edge [arrowhead=vee,fontname=\"Arial\",fontsize=40,color=\"steelblue4\"];q1 [label=\"Prescription from Endocrinologist or Weight Management Specialist?\"]q2 [label=\"Patient at least 18 years of age?\"]q3 [label=\"Baseline BMI 30 kg/m2 or greater with at least one weight-related comorbidity?\"]q4 [label=\"Patient has attempted to lose weight through KP-approved weight loss program?\"]q5 [label=\"Patient has documented intolerance or contraindication to all listed medications?\"]q6 [label=\"Wegovy not used with another weight loss drug or GLP-1 receptor agonist?\"]q7 [label=\"Initial prescription is limited to a maximum of 30-day supply with 2 refills?\"]q8 [label=\"For Type 2 DM patients,do they meet both additional criteria?\"]q9 [label=\"Patient continues to meet initial review criteria?\"]q10 [label=\"Documented weight loss of at least 10% from baseline weight in the past 3 months?\"]ineligible [label=\"Ineligible\", color=\"red\"]eligible [label=\"Eligible\", color=\"darkgreen\"]q1 -> q2 [label=\"Yes\"]q1 -> ineligible [label=\"No\"]q2 -> q3 [label=\"Yes\"]q2 -> ineligible [label=\"No\"]q3 -> q4 [label=\"Yes\"]q3 -> ineligible [label=\"No\"]q4 -> q5 [label=\"Yes\"]q4 -> ineligible [label=\"No\"]q5 -> q6 [label=\"Yes\"]q5 -> ineligible [label=\"No\"]q6 -> q7 [label=\"Yes\"]q6 -> ineligible [label=\"No\"]q7 -> q8 [label=\"Yes\"]q7 -> ineligible [label=\"No\"]q8 -> q9 [label=\"Yes\"]q8 -> ineligible [label=\"No\"]q9 -> q10 [label=\"Yes\"]q9 -> ineligible [label=\"No\"]q10 -> eligible [label=\"Yes\"]q10 -> ineligible [label=\"No\"]}",
            "requirements_flow_file_location": "graphs/wegovy-united-healthcare.svg",
            "requirements_checklist": {
                "label": "Is this request for initiation or continuation of therapy with Wegovy™ (semaglutide)?",
                "node_type": "fieldset",
                "children": [
                    {
                        "label": "Start of therapy",
                        "outcome": "Authorization for Wegovy™ (semaglutide), is expected to be issued for 4 months",
                        "node_type": "radio",
                        "node_value": false,
                        "children": [
                            {
                                "label": "Treatment is being requested for appetite suppression or weight loss",
                                "node_type": "checkbox",
                                "node_value": false
                            },
                            {
                                "label": "Patient is ≥ 12 years of age",
                                "node_type": "checkbox",
                                "node_value": false
                            },
                            {
                                "label": "Used as an adjunct to lifestyle modification (e.g., dietary or caloric restriction, exercise, behavioral support, community-based program)",
                                "node_type": "checkbox",
                                "node_value": false
                            },
                            {
                                "label": "One of the following",
                                "node_type": "checkbox",
                                "node_value": false,
                                "children": [
                                    {
                                        "label": "Body Mass Index (BMI) ≥ 30 kg/m2 or for pediatric patients a BMI > 95th percentile",
                                        "node_type": "checkbox",
                                        "node_value": false
                                    },
                                    {
                                        "label": "BMI ≥ 27 kg/m2 and patient has a weight-related comorbidity (e.g., dyslipidemia, hypertension, type 2 diabetes, sleep apnea)",
                                        "node_type": "checkbox",
                                        "node_value": false
                                    }
                                ]
                            }
                        ]
                    },
                    {
                        "label": "Continuation of therapy",
                        "outcome": "Authorization for Wegovy™ (semaglutide), is expected to be issued for 12 months",
                        "node_type": "radio",
                        "node_value": false,
                        "children": [
                            {
                                "label": "Weight loss of ≥ 4% of baseline body weight for Wegovy",
                                "node_type": "checkbox",
                                "node_value": false
                            },
                            {
                                "label": "Continuation of lifestyle modification",
                                "node_type": "checkbox",
                                "node_value": false
                            }
                        ]
                    }
                ]
            }
        }
    },
    {
        "model": "portal.PriorAuthRequirement",
        "pk": 5,
        "fields": {
            "url_slug": "117b9ebfe4f23327",
            "description": "Kaiser Permenante Prior Authorization Requirements for Wegovy",
            "insurance_provider": "Kaiser Permenante",
            "insurance_plan_number": "",
            "insurance_coverage_state": "",
            "medication": "Wegovy",
            "requirements_flow_file_location": "graphs/wegovy-kaiser-permenante.svg",
            "requirements_flow": "digraph G { node[shape=box, style = \"filled,rounded\", color = \"steelblue4\" fontcolor = \"mintcream\", fontname = \"Arial\", margin = 0.1 fontsize = 40, width = 0.2, height = 0.2, ]; edge [arrowhead=vee,fontname=\"Arial\",fontsize=40,color=\"steelblue4\"]; node1 [label=\"Who is the prescriber?\", shape=box]; node2 [label=\"What is the patient's age?\", shape=box]; node3 [label=\"What is the starting BMI?\", shape=box]; node4 [label=\"Does the patient have an additional diagnosis from this list?\n cardiovascular disease,\n stroke,\n hypertension,\n Type 2 DM,\n CKD,\n CHD,\n obstructive sleep apnea,\n polycystic ovarian syndrome,\n dyslipidemia,\n non-alcoholic fatty liver disease,\n idiopathic intracranial hypertension,\n osteoarthritis in weight-bearing joints\", shape=box]; node5 [label=\"Is the starting weight in your records?\", shape=box]; node6 [label=\"Patient enrolled in KP-approved weight loss program?\", shape=box]; node7 [label=\"Failure to lose 5% weight after 3-month trial of the following medications?\n (Xenical,\n Contrave,\n Qsymia,\n Saxenda)\", shape=box]; node8 [label=\"Wegovy used with another weight loss drug?\", shape=box]; node9 [label=\"Initial Wegovy prescription is 30-day supply with 2 refills?\", shape=box]; node10 [label=\"Does patient have Type 2 DM?\", shape=box]; node11 [label=\"Following KP National Adult DM Guidelines?\", shape=box]; node12 [label=\"Failed to reach goal A1c after 6-month trial of Victoza and Ozempic?\", shape=box]; node13 [label=\"Does the patient continue to meet the initial review criteria?\", shape=box]; node14 [label=\"What is the percentage of weight loss from starting weight in the last 3 months?\", shape=box]; notEligible [label=\"Not Eligible\", shape=box, color=red]; eligible [label=\"Eligible\", shape=box, color=darkgreen]; node1 -> node2 [label=\"Endocrinologist or Weight Management Specialist\"]; node1 -> notEligible [label=\"Other\"]; node2 -> node3 [label=\"18 or older\"]; node2 -> notEligible [label=\"Younger than 18\"]; node3 -> node4 [label=\"30 kg/m^2 or greater\"]; node3 -> notEligible [label=\"Less than 30 kg/m^2\"]; node4 -> node5 [label=\"Yes\"]; node4 -> notEligible [label=\"No\"]; node5 -> node6 [label=\"Yes\"]; node5 -> notEligible [label=\"No\"]; node6 -> node7 [label=\"Yes\"]; node6 -> notEligible [label=\"No\"]; node7 -> node8 [label=\"Yes\"]; node7 -> notEligible [label=\"No\"]; node8 -> node9 [label=\"No\"]; node8 -> notEligible [label=\"Yes\"]; node9 -> node10 [label=\"Yes\"]; node9 -> notEligible [label=\"No\"]; node10 -> node11 [label=\"Yes\"]; node10 -> node13 [label=\"No\"]; node11 -> node12 [label=\"Yes\"]; node11 -> notEligible [label=\"No\"]; node12 -> node13 [label=\"Yes\"]; node12 -> notEligible [label=\"No\"]; node13 -> node14 [label=\"Yes\"]; node13 -> notEligible [label=\"No\"]; node14 -> eligible [label=\"At least 10%\"]; node14 -> notEligible [label=\"Less than 10%\"]; }",
            "requirements_checklist": {
                "label": "Is this request for starting or continued therapy with Wegovy™ (semaglutide)?",
                "node_type": "fieldset",
                "children": [
                    {
                        "label": "Initial review criteria",
                        "outcome": "The requested drug, Wegovy™ (semaglutide), is expected to be covered with prior authorization for 3 months",
                        "node_type": "radio",
                        "node_value": false,
                        "children": [
                            {
                                "label": "Prescribed by Endocrinologist or Weight Management Specialist",
                                "node_type": "checkbox",
                                "node_value": false
                            },
                            {
                                "label": "Patient at least 18 years of age",
                                "node_type": "checkbox",
                                "node_value": false
                            },
                            {
                                "label": "Baseline BMI 30 kg/m2 or greater with at least one of the following weight-related comorbidities:",
                                "node_type": "checkbox",
                                "node_value": false,
                                "children": [
                                    {
                                        "label": "Established cardiovascular disease or stroke",
                                        "node_type": "checkbox",
                                        "node_value": false
                                    },
                                    {
                                        "label": "Hypertension",
                                        "node_type": "checkbox",
                                        "node_value": false
                                    },
                                    {
                                        "label": "Type 2 DM",
                                        "node_type": "checkbox",
                                        "node_value": false
                                    },
                                    {
                                        "label": "CKD",
                                        "node_type": "checkbox",
                                        "node_value": false
                                    },
                                    {
                                        "label": "CHD",
                                        "node_type": "checkbox",
                                        "node_value": false
                                    },
                                    {
                                        "label": "Obstructive sleep apnea",
                                        "node_type": "checkbox",
                                        "node_value": false
                                    },
                                    {
                                        "label": "Polycystic ovarian syndrome",
                                        "node_type": "checkbox",
                                        "node_value": false
                                    },
                                    {
                                        "label": "Dyslipidemia",
                                        "node_type": "checkbox",
                                        "node_value": false
                                    },
                                    {
                                        "label": "Non-alcoholic fatty liver disease",
                                        "node_type": "checkbox",
                                        "node_value": false
                                    },
                                    {
                                        "label": "Idiopathic intracranial hypertension",
                                        "node_type": "checkbox",
                                        "node_value": false
                                    },
                                    {
                                        "label": "Osteoarthritis in weight-bearing joints",
                                        "node_type": "checkbox",
                                        "node_value": false
                                    }
                                ]
                            },
                            {
                                "label": "Documented baseline weight",
                                "node_type": "checkbox",
                                "node_value": false
                            },
                            {
                                "label": "Patient has attempted to lose weight through a KP-approved weight loss program, and will continue these interventions while on Wegovy",
                                "node_type": "checkbox",
                                "node_value": false
                            },
                            {
                                "label": "Patient has documented intolerance, contraindication or failure to lose and maintain greater than or equal to 5% body weight after a 3-month trial of ALL of the following medications indicated for chronic weight management:",
                                "node_type": "checkbox",
                                "node_value": false,
                                "all_required": true,
                                "children": [
                                    {
                                        "label": "Xenical (orlistat)",
                                        "node_type": "checkbox",
                                        "node_value": false
                                    },
                                    {
                                        "label": "Contrave (naltrexone + bupropion)",
                                        "node_type": "checkbox",
                                        "node_value": false
                                    },
                                    {
                                        "label": "Qsymia (phentermine + topiramate)",
                                        "node_type": "checkbox",
                                        "node_value": false
                                    },
                                    {
                                        "label": "Saxenda (liraglutide)",
                                        "node_type": "checkbox",
                                        "node_value": false
                                    }
                                ]
                            },
                            {
                                "label": "Wegovy is not being used in combination with another weight loss drug or GLP-1 receptor agonist",
                                "node_type": "checkbox",
                                "node_value": false
                            },
                            {
                                "label": "Initial prescription is limited to a maximum of 30-day supply with 2 refills",
                                "node_type": "checkbox",
                                "node_value": false
                            },
                            {
                                "label": "For patients with Type 2 DM and BMI of 30 kg/m2 or greater, must meet both additional criteria below:",
                                "node_type": "checkbox",
                                "node_value": false,
                                "all_required": true,
                                "children": [
                                    {
                                        "label": "Must follow KP National Adult DM Guidelines and CBC step therapy criteria for use of preferred agents for DM control",
                                        "node_type": "checkbox",
                                        "node_value": false
                                    },
                                    {
                                        "label": "Documented intolerance, contraindication, or failure to reach goal A1c after at least 6 month trial of Victoza and Ozempic",
                                        "node_type": "checkbox",
                                        "node_value": false
                                    }
                                ]
                            }
                        ]
                    },
                    {
                        "label": "Continuation of therapy",
                        "outcome": "The requested drug, Wegovy™ (semaglutide), is expected to be covered with prior authorization for 6 months",
                        "node_type": "radio",
                        "node_value": false,
                        "children": [
                            {
                                "label": "Patient continues to meet initial review criteria",
                                "node_type": "checkbox",
                                "node_value": false
                            },
                            {
                                "label": "Documented weight loss within the previous 3 months of at least 10% from baseline weight",
                                "node_type": "checkbox",
                                "node_value": false
                            }
                        ]
                    }
                ]
            }
        }
    },
    {
        "model": "portal.PriorAuthRequirement",
        "pk": 6,
        "fields": {
            "url_slug": "845c97103fa2b215",
            "description": "CVS Caremark Prior Authorization Requirements for Wegovy",
            "insurance_provider": "CVS Caremark",
            "insurance_plan_number": "",
            "insurance_coverage_state": "",
            "medication": "Wegovy",
            "requirements_flow_file_location": "graphs/wegovy-cvs-caremark.svg",
            "requirements_flow": "digraph G {ranksep=1; node[shape=box, style=\"filled,rounded\", color=\"steelblue4\", fontcolor=\"mintcream\", fontname=\"Arial\", margin=0.1, fontsize=40, width=0.2, height=0.2];edge [arrowhead=vee,fontname=\"Arial\",fontsize=40,color=\"steelblue4\"];notEligible [label=\"Not Eligible\", shape=box, color=red];eligible [label=\"Eligible\", shape=box, color=darkgreen];start [label=\"Starting or Continuing Therapy?\", shape=box]; {    rank=same;     node1 [label=\"Is Wegovy being used with reduced-calorie diet and increased physical activity?\", shape=box];     node5 [label=\"Has the patient completed at least 3 months of therapy with Wegovy at a stable maintenance dose?\", shape=box];}{    rank=same;     node2 [label=\"Has the patient participated in a comprehensive weight management program for at least 6 months prior?\", shape=box];     node6 [label=\"What is the percentage of weight loss from the baseline body weight?\", shape=box];}node3 [label=\"What is the patient's BMI?\", shape=box];{    rank=same;     node4 [label=\"Does the patient have a weight-related comorbidity? \n (e.g., hypertension, type 2 diabetes mellitus, dyslipidemia)\", shape=box];     node7 [label=\"Is there a documentation of the above weight loss?\", shape=box];}start -> node1 [label=\"Starting\", weight=1];start -> node5 [label=\"Continuing\", weight=1];node1 -> node2 [label=\"Yes\", weight=1];node1 -> notEligible [label=\"No\", weight=1];node2 -> node3 [label=\"Yes\", weight=1];node2 -> notEligible [label=\"No\", weight=1];node3 -> node4 [label=\">=27 and <=29 kg/m^2\", weight=1];node3 -> eligible [label=\">=30 kg/m^2\", weight=1];node3 -> notEligible [label=\"<27 kg/m^2\", weight=1];node4 -> eligible [label=\"Yes\", weight=1];node4 -> notEligible [label=\"No\", weight=1];node5 -> node6 [label=\"Yes\", weight=1];node5 -> notEligible [label=\"No\", weight=1];node6 -> node7 [label=\">=5% weight loss\nor\nMaintained initial 5% weight loss\", weight=1];node6 -> notEligible [label=\"Weight loss criteria not met\", weight=1];node7 -> eligible [label=\"Yes\", weight=1];node7 -> notEligible [label=\"No\", weight=1];}",
            "requirements_checklist": {
                "label": "Is this request for starting or continued therapy with Wegovy™ (semaglutide)?",
                "node_type": "fieldset",
                "children": [
                    {
                        "label": "Starting therapy",
                        "outcome": "The requested drug, Wegovy™ (semaglutide), is expected to be covered with prior authorization",
                        "node_type": "radio",
                        "node_value": false,
                        "children": [
                            {
                                "label": "The requested drug, Wegovy™ (semaglutide), will be used in conjunction with a reduced-calorie diet and increased physical activity for chronic weight management in an adult.",
                                "node_type": "checkbox",
                                "node_value": false
                            },
                            {
                                "label": "The patient has participated in a comprehensive weight management program that encourages behavioral modification, a reduced calorie diet, and increased physical activity with continuing follow-up for at least 6 months prior to using drug therapy.",
                                "node_type": "checkbox",
                                "node_value": false
                            },
                            {
                                "label": "The patient's Body Mass Index (BMI) meets one of the following conditions:",
                                "node_type": "checkbox",
                                "node_value": false,
                                "children": [
                                    {
                                        "label": "The patient has a BMI greater than or equal to 30 kg/m²",
                                        "node_type": "checkbox",
                                        "node_value": false
                                    },
                                    {
                                        "label": "The patient has a BMI greater than or equal to 27 kg/m² AND has at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)",
                                        "node_type": "checkbox",
                                        "node_value": false
                                    }
                                ]
                            }
                        ]
                    },
                    {
                        "label": "Continuation of therapy",
                        "outcome": "The requested drug, Wegovy™ (semaglutide), is expected to be covered with prior authorization",
                        "node_type": "radio",
                        "node_value": false,
                        "children": [
                            {
                                "label": "The patient has completed at least 3 months of therapy with the requested drug at a stable maintenance dose",
                                "node_type": "checkbox",
                                "node_value": false
                            },
                            {
                                "label": "The patient has either:",
                                "node_type": "checkbox",
                                "node_value": false,
                                "children": [
                                    {
                                        "label": "Lost at least 5 percent of baseline body weight",
                                        "node_type": "checkbox",
                                        "node_value": false
                                    },
                                    {
                                        "label": "Continued to maintain their initial 5 percent weight loss",
                                        "node_type": "checkbox",
                                        "node_value": false
                                    }
                                ]
                            },
                            {
                                "label": "Documentation of the above weight loss is provided.",
                                "node_type": "checkbox",
                                "node_value": false
                            }
                        ]
                    }
                ]
            }
        }
    },
    {
        "model": "portal.PriorAuthRequirement",
        "pk": 7,
        "fields": {
            "url_slug": "863e71923ab8cfc3",
            "description": "Aetna Prior Authorization Requirements for Wegovy",
            "insurance_provider": "Aetna",
            "insurance_plan_number": "",
            "insurance_coverage_state": "",
            "medication": "Wegovy",
            "requirements_flow_file_location": "graphs/wegovy-aetna.svg",
            "requirements_flow": "",
            "requirements_checklist": {
                "label": "Age of patient?",
                "node_type": "fieldset",
                "children": [
                    {
                        "label": "For patients 18 years or older",
                        "outcome": "Authorization for Wegovy™ (semaglutide), may be approved when all of the criteria are met",
                        "node_type": "radio",
                        "node_value": false,
                        "children": [
                            {
                                "label": "Is this request for initiation or continuation of therapy with Wegovy™ (semaglutide)?",
                                "node_type": "fieldset",
                                "children": [
                                    {
                                        "label": "Start of therapy",
                                        "outcome": "Authorization for Wegovy™ (semaglutide), may be approved when all of the criteria are met",
                                        "node_type": "radio",
                                        "node_value": false,
                                        "children": [
                                            {
                                                "label": "The patient is 18 years of age or older",
                                                "node_type": "checkbox",
                                                "node_value": false
                                            },
                                            {
                                                "label": "The patient has participated in a comprehensive weight management program that encourages behavioral modification, reduced-calorie diet, and increased physical activity with a continuing follow-up for at least 6 months prior to using drug therapy",
                                                "node_type": "checkbox",
                                                "node_value": false
                                            },
                                            {
                                                "label": "The patient has either:",
                                                "node_type": "checkbox",
                                                "node_value": false,
                                                "children": [
                                                    {
                                                        "label": "A body mass index (BMI) greater than or equal to 30 kilogram per square meter",
                                                        "node_type": "checkbox",
                                                        "node_value": false
                                                    },
                                                    {
                                                        "label": "A body mass index (BMI) greater than or equal to 27 kilogram per square meter AND has at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus or dyslipidemia)",
                                                        "node_type": "checkbox",
                                                        "node_value": false
                                                    }
                                                ]
                                            }
                                        ]
                                    },
                                    {
                                        "label": "Continuation of therapy",
                                        "outcome": "Authorization for Wegovy™ (semaglutide), may be approved when all of the criteria are met",
                                        "node_type": "radio",
                                        "node_value": false,
                                        "children": [
                                            {
                                                "label": "The patient has completed at least 3 months of therapy with the requested drug at a stable maintenance dose",
                                                "node_type": "checkbox",
                                                "node_value": false
                                            },
                                            {
                                                "label": "The patient has either:",
                                                "node_type": "checkbox",
                                                "node_value": false,
                                                "children": [
                                                    {
                                                        "label": "Lost at least 5 percent of baseline body weight",
                                                        "node_type": "checkbox",
                                                        "node_value": false
                                                    },
                                                    {
                                                        "label": "Continued to maintain their initial 5 percent weight loss (Documentation is required)",
                                                        "node_type": "checkbox",
                                                        "node_value": false
                                                    }
                                                ]
                                            },
                                            {
                                                "label": "The requested drug will be used with a reduced-calorie diet and increased physical activity for chronic weight management",
                                                "node_type": "checkbox",
                                                "node_value": false
                                            }
                                        ]
                                    }
                                ]
                            }
                        ]
                    },
                    {
                        "label": "For patients aged 12 to 17 years",
                        "outcome": "Authorization for Wegovy™ (semaglutide), may be approved when all of the criteria are met",
                        "node_type": "radio",
                        "node_value": false,
                        "children": [
                            {
                                "label": "Is this request for initiation or continuation of therapy with Wegovy™ (semaglutide)?",
                                "node_type": "fieldset",
                                "children": [
                                    {
                                        "label": "Start of therapy",
                                        "outcome": "Authorization for Wegovy™ (semaglutide), may be approved when all of the criteria are met",
                                        "node_type": "radio",
                                        "node_value": false,
                                        "children": [
                                            {
                                                "label": "The patient is 12 to 17 years of age",
                                                "node_type": "checkbox",
                                                "node_value": false
                                            },
                                            {
                                                "label": "The requested drug will be used with a reduced-calorie diet and increased physical activity for chronic weight management",
                                                "node_type": "checkbox",
                                                "node_value": false
                                            },
                                            {
                                                "label": "The patient has participated in a comprehensive weight management program that encourages behavioral modification, reduced-calorie diet, and increased physical activity with continuing follow-up for at least 6 months prior to using drug therapy",
                                                "node_type": "checkbox",
                                                "node_value": false
                                            },
                                            {
                                                "label": "The patient has an initial body mass index (BMI) in the 95th percentile or greater standardized for age and sex (obesity)",
                                                "node_type": "checkbox",
                                                "node_value": false
                                            }
                                        ]
                                    },
                                    {
                                        "label": "Continuation of therapy",
                                        "outcome": "Authorization for Wegovy™ (semaglutide), is expected to be issued for 12 months",
                                        "node_type": "radio",
                                        "node_value": false,
                                        "children": [
                                            {
                                                "label": "The patient has either",
                                                "node_type": "checkbox",
                                                "node_value": false,
                                                "children": [
                                                    {
                                                        "label": "A reduction from their baseline body mass index (BMI)",
                                                        "node_type": "checkbox",
                                                        "node_value": false
                                                    },
                                                    {
                                                        "label": "Continued to maintain their reduction in BMI from baseline (Documentation is required)",
                                                        "node_type": "checkbox",
                                                        "node_value": false
                                                    }
                                                ]
                                            }
                                        ]
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        }
    }
]